Pfizer announced that the FDA has approved Inlyta (axitinib) for the treatment of patients with advanced renal cell carcinoma who have not responded to another drug for this type of cancer. This approval was based on data from a randomized, open-label, multicenter clinical study of 723 patients whose disease had progressed on or after treatment with one prior systemic therapy. The primary efficacy endpoint of the study was progression-free survival (PFS). Results showed a median PFS of 6.7 months compared with 4.7 months with a standard treatment (sorafenib).

Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, receptors that can influence tumor growth, vascular angiogenesis and progression of cancer (the spread of tumors).

For more information, call (800) 438-1985 or visit